OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Medical Virology is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
The neuroinvasive potential of SARS‐CoV2 may play a role in the respiratory failure of COVID‐19 patients	1404
Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis	1082
Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID‐19) implicate special control measures	941
The cytokine storm and COVID‐19	916
Tocilizumab treatment in COVID‐19: A single center experience	913
Postdischarge symptoms and rehabilitation needs in survivors of COVID‐19 infection: A cross‐sectional evaluation	896
COVID‐19 patients' clinical characteristics, discharge rate, and fatality rate of meta‐analysis	862
Potential interventions for novel coronavirus in China: A systematic review	793
Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS‐CoV‐2 infection	762
Central nervous system involvement by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)	698
Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID‐19	664
Clinical features and treatment of COVID‐19 patients in northeast Chongqing	644
Understanding of COVID‐19 based on current evidence	637
The presence of SARS‐CoV‐2 RNA in the feces of COVID‐19 patients	609
Omicron variant of SARS‐CoV‐2: Genomics, transmissibility, and responses to current COVID‐19 vaccines	541
Coronavirus disease 2019: What we know?	515
The impact of COPD and smoking history on the severity of COVID‐19: A systemic review and meta‐analysis	476
Stability issues of RT‐PCR testing of SARS‐CoV‐2 for hospitalized patients clinically diagnosed with COVID‐19	461
Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS‐CoV‐2	458
Predictors of mortality in hospitalized COVID‐19 patients: A systematic review and meta‐analysis	426
Clinical characteristics of 3062 COVID‐19 patients: A meta‐analysis	406
Elevated interleukin‐6 and severe COVID‐19: A meta‐analysis	398
Transmission dynamics of the COVID‐19 outbreak and effectiveness of government interventions: A data‐driven analysis	397
Epidemiology of COVID‐19: A systematic review and meta‐analysis of clinical characteristics, risk factors, and outcomes	391
Neutrophil‐to‐lymphocyte ratio and lymphocyte‐to‐C‐reactive protein ratio in patients with severe coronavirus disease 2019 (COVID‐19): A meta‐analysis	383

Omicron and Delta variant of SARS‐CoV‐2: A comparative computational study of spike protein	381
False negative of RT‐PCR and prolonged nucleic acid conversion in COVID‐19: Rather than recurrence	377
The establishment of reference sequence for SARS‐CoV‐2 and variation analysis	357
C‐reactive protein correlates with computed tomographic findings and predicts severe COVID‐19 early	349
Platelet‐to‐lymphocyte ratio is associated with prognosis in patients with coronavirus disease‐19	345
Organ‐protective effect of angiotensin‐converting enzyme 2 and its effect on the prognosis of COVID‐19	339
In silico studies on the comparative characterization of the interactions of SARS‐CoV‐2 spike glycoprotein with ACE‐2 receptor homologs and human TLRs	326
A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option	308
Clinical characteristics of hospitalized patients with SARS‐CoV‐2 infection: A single arm meta‐analysis	306
The emergence and epidemic characteristics of the highly mutated SARS‐CoV‐2 Omicron variant	306
Post‐acute COVID‐19 syndrome (PCS) and health‐related quality of life (HRQoL)—A systematic review and meta‐analysis	303
Evolutionary history, potential intermediate animal host, and cross‐species analyses of SARS‐CoV‐2	299
Combination of RT‐qPCR testing and clinical features for diagnosis of COVID‐19 facilitates management of SARS‐CoV‐2 outbreak	297
COVID‐19 epidemic: Disease characteristics in children	293
Development of epitope‐based peptide vaccine against novel coronavirus 2019 (SARS‐COV‐2): Immunoinformatics approach	287
Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China	286
The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China	282
Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta‐analysis	282
Fecal specimen diagnosis 2019 novel coronavirus–infected pneumonia	280
Vaccine hesitancy: Beliefs and barriers associated with COVID‐19 vaccination among Egyptian medical students	277
The effect of smoking on COVID‐19 severity: A systematic review and meta‐analysis	269
Structural variations in human ACE2 may influence its binding with SARS‐CoV‐2 spike protein	260
SARS‐CoV‐2 can be detected in urine, blood, anal swabs, and oropharyngeal swabs specimens	248
Role of Toll‐like receptors in the pathogenesis of COVID‐19	243
The effectiveness of quarantine of Wuhan city against the Corona Virus Disease 2019 (COVID‐19): A well‐mixed SEIR model analysis	232
A systematic review and meta‐analysis of children with coronavirus disease 2019 (COVID‐19)	226
Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID‐19	224
Immunoinformatics‐aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019‐nCoV	220
Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review	219
Imaging and clinical features of patients with 2019 novel coronavirus SARS‐CoV‐2: A systematic review and meta‐analysis	213
Potential utilities of mask‐wearing and instant hand hygiene for fighting SARS‐CoV‐2	211
Hypoalbuminemia predicts the outcome of COVID‐19 independent of age and co‐morbidity	211
Coronavirus disease (COVID‐19) and neonate: What neonatologist need to know	208
Elevated level of C‐reactive protein may be an early marker to predict risk for severity of COVID‐19	207
Characterization of the novel SARS‐CoV‐2 Omicron (B.1.1.529) variant of concern and its global perspective	206
The potential chemical structure of anti‐SARS‐CoV‐2 RNA‐dependent RNA polymerase	201
Obesity aggravates COVID‐19: A systematic review and meta‐analysis	199
OMICRON (B.1.1.529): A new SARS‐CoV‐2 variant of concern mounting worldwide fear	194
Current evidence on efficacy of COVID‐19 booster dose vaccination against the Omicron variant: A systematic review	181
Evaluation of sex‐related hormones and semen characteristics in reproductive‐aged male COVID‐19 patients	179
A comparison study of SARS‐CoV‐2 IgG antibody between male and female COVID‐19 patients: A possible reason underlying different outcome between sex	175
Performance of VivaDiag COVID‐19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID‐19 in acute patients referring to emergency room department	171
Analysis of heart injury laboratory parameters in 273 COVID‐19 patients in one hospital in Wuhan, China	171
Psychological stress of medical staffs during outbreak of COVID‐19 and adjustment strategy	170
Sequence analysis of the emerging SARS‐CoV‐2 variant Omicron in South Africa	170
The value of clinical parameters in predicting the severity of COVID‐19	169
Tocilizumab for the treatment of severe coronavirus disease 2019	168
The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID‐19): A Chinese perspective	168
Epidemiological trends and clinical features of the ongoing monkeypox epidemic: A preliminary pooled data analysis and literature review	166
Coinfection in SARS‐CoV‐2 infected patients: Where are influenza virus and rhinovirus/enterovirus?	165

Relative instantaneous reproduction number of Omicron SARS‐CoV‐2 variant with respect to the Delta variant in Denmark	156
Detection profile of SARS‐CoV‐2 using RT‐PCR in different types of clinical specimens: A systematic review and meta‐analysis	154
Chronic COVID syndrome: Need for an appropriate medical terminology for long‐COVID and COVID long‐haulers	154
Emerging coronaviruses: Genome structure, replication, and pathogenesis	151
Evaluation of SARS‐CoV‐2 neutralizing antibodies using a CPE‐based colorimetric live virus micro‐neutralization assay in human serum samples	146
Detectable SARS‐CoV‐2 viral RNA in feces of three children during recovery period of COVID‐19 pneumonia	145
Omicron variant (B.1.1.529) of SARS‐CoV‐2, a global urgent public health alert!	145
Virological and clinical cure in COVID‐19 patients treated with hydroxychloroquine: A systematic review and meta‐analysis	140
Prolonged SARS‐CoV‐2 RNA shedding: Not a rare phenomenon	140
Clinical characteristics and outcomes of cancer patients with COVID‐19	140
SARS‐CoV‐2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG‐I/MDA‐5–MAVS, TLR3–TRIF, and cGAS–STING signaling pathways	139
Hyperglycemia, hydroxychloroquine, and the COVID‐19 pandemic	139
From SARS and MERS CoVs to SARS‐CoV‐2: Moving toward more biased codon usage in viral structural and nonstructural genes	139
Should RT‐PCR be considered a gold standard in the diagnosis of COVID‐19?	138
Estimation of the basic reproduction number, average incubation time, asymptomatic infection rate, and case fatality rate for COVID‐19: Meta‐analysis and sensitivity analysis	134
Encephalopathy in patients with COVID‐19: A review	134
A brief review of influenza virus infection	134
Omicron variant genome evolution and phylogenetics	133
Early phylogenetic estimate of the effective reproduction number of SARS‐CoV‐2	132
Characteristics of patients with coronavirus disease (COVID‐19) confirmed using an IgM‐IgG antibody test	131
Clinical characteristics of 54 medical staff with COVID‐19: A retrospective study in a single center in Wuhan, China	129
Vitamin D insufficiency as a potential culprit in critical COVID‐19 patients	126
The epidemiology and clinical characteristics of co‐infection of SARS‐CoV‐2 and influenza viruses in patients during COVID‐19 outbreak	125
A large‐scale meta‐analytic atlas of mental health problems prevalence during the COVID‐19 early pandemic	125
Analyzing the epidemiological outbreak of COVID‐19: A visual exploratory data analysis approach	125
High IL‐6/IFN‐γ ratio could be associated with severe disease in COVID‐19 patients	124
Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus‐associated illnesses	121
Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Spike mutation T478K	121
Mathematical modeling of interaction between innate and adaptive immune responses in COVID‐19 and implications for viral pathogenesis	119
Diagnostic accuracy of an automated chemiluminescent immunoassay for anti‐SARS‐CoV‐2 IgM and IgG antibodies: an Italian experience	119
Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross‐sectional study	119
Emergence of Omicron third lineage BA.3 and its importance	118
Analysis of 92 deceased patients with COVID‐19	118
Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID‐19	117
Extrapulmonary complications of COVID‐19: A multisystem disease?	116
The anti‐HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV‐2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID‐19 infe	115
Initial clinical features of suspected coronavirus disease 2019 in two emergency departments outside of Hubei, China	113
Conjunctivitis and COVID‐19: A meta‐analysis	113
Analyzing situational awareness through public opinion to predict adoption of social distancing amid pandemic COVID‐19	111
Distinct viral clades of SARS‐CoV‐2: Implications for modeling of viral spread	109
Epidemiological evidence for association between higher influenza vaccine uptake in the elderly and lower COVID‐19 deaths in Italy	108
Influenza and COVID‐19 coinfection: Report of six cases and review of the literature	107
SARS‐CoV‐2 spike protein favors ACE2 from Bovidae and Cricetidae	106
Multisystem inflammatory syndrome in children related to COVID‐19: A New York City experience	106
Anxiety and depression symptoms after virological clearance of COVID‐19: A cross‐sectional study in Milan, Italy	104
Omicron (BA.1) and sub‐variants (BA.1.1, BA.2, and BA.3) of SARS‐CoV‐2 spike infectivity and pathogenicity: A comparative sequence and structural‐based computational assessment	104
Long COVID and chronic COVID syndromes	104
Co‐infection of SARS‐CoV‐2 and HIV in a patient in Wuhan city, China	102
Obesity aggravates COVID‐19: An updated systematic review and meta‐analysis	102
Long COVID syndrome‐associated brain fog	101
The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019	100
Safety of COVID‐19 vaccines	100
Genomic characterization and phylogenetic analysis of SARS‐COV‐2 in Italy	99
An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID‐19	98
Clinical performance of different SARS‐CoV‐2 IgG antibody tests	98
Expression of the COVID‐19 receptor ACE2 in the human conjunctiva	98
Droplet digital PCR of viral ‎DNA/RNA, current progress, challenges, and future perspectives	97
Clinical analysis of pregnant women with 2019 novel coronavirus pneumonia	97
Non‐life‐threatening adverse effects with COVID‐19 mRNA‐1273 vaccine: A randomized, cross‐sectional study on healthcare workers with detailed self‐reported symptoms	96
Asymptomatic SARS‐CoV‐2 infected case with viral detection positive in stool but negative in nasopharyngeal samples lasts for 42 days	96
The “post‐COVID” syndrome: How deep is the damage?	95
Response to Commentary on “The neuroinvasive potential of SARS‐CoV‐2 may play a role in the respiratory failure of COVID‐19 patients”	93
Potential neuroinvasive pathways of SARS‐CoV‐2: Deciphering the spectrum of neurological deficit seen in coronavirus disease‐2019 (COVID‐19)	93
Where have all the viruses gone? Disappearance of seasonal respiratory viruses during the COVID‐19 pandemic	92
Epidemiological analysis of COVID‐19 and practical experience from China	92
Increasing host cellular receptor—angiotensin‐converting enzyme 2 expression by coronavirus may facilitate 2019‐nCoV (or SARS‐CoV‐2) infection	92
Risk factors prediction, clinical outcomes, and mortality in COVID‐19 patients	91
Evolutionary dynamics of SARS‐CoV‐2 nucleocapsid protein and its consequences	91
Bacterial infections and patterns of antibiotic use in patients with COVID‐19	90
Clinical trial analysis of 2019‐nCoV therapy registered in China	89
Anemia is associated with severe illness in COVID‐19: A retrospective cohort study	88
Autoimmune complications of COVID‐19	87
Hepatic involvement in COVID‐19 patients: Pathology, pathogenesis, and clinical implications	87
Retest positive for SARS‐CoV‐2 RNA of “recovered” patients with COVID‐19: Persistence, sampling issues, or re‐infection?	86
Off‐label use of tocilizumab in patients with SARS‐CoV‐2 infection	85
Targeting human TLRs to combat COVID‐19: A solution?	85
CT imaging features of 4121 patients with COVID‐19: A meta‐analysis	84
Causes of hypogeusia/hyposmia in SARS‐CoV2 infected patients	83
SARS‐CoV‐2: A comprehensive review from pathogenicity of the virus to clinical consequences	83
Comparative analysis of antiviral efficacy of FDA‐approved drugs against SARS‐CoV‐2 in human lung cells	82

Association between tuberculosis and COVID‐19 severity and mortality: A rapid systematic review and meta‐analysis	82
A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019‐nCoV)	82
Correlation between a quantitative anti‐SARS‐CoV‐2 IgG ELISA and neutralization activity	82
Detection of antibodies against SARS‐CoV‐2 in patients with COVID‐19	82
Alert for non‐respiratory symptoms of coronavirus disease 2019 patients in epidemic period: A case report of familial cluster with three asymptomatic COVID‐19 patients	81
Evaluation of seven commercial RT‐PCR kits for COVID‐19 testing in pooled clinical specimens	81
Hepatic complications of COVID‐19 and its treatment	81
Characterization of the significant decline in humoral immune response six months post‐SARS‐CoV‐2 mRNA vaccination: A systematic review	81
Post‐COVID syndrome: A single‐center questionnaire study on 1007 participants recovered from COVID‐19	80
Effects of SARS‐CoV‐2 mutations on protein structures and intraviral protein–protein interactions	80
Genomic annotation and molecular evolution of monkeypox virus outbreak in 2022	80
Comparison of SARS‐CoV‐2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARS‐CoV‐2 test and a laboratory‐developed real‐time RT‐PCR test	80
Human herpesvirus‐6, ‐7, and Epstein‐Barr virus reactivation in pityriasis rosea during COVID‐19	79
Concomitant neurological symptoms observed in a patient diagnosed with coronavirus disease 2019	79
Clinical outcomes in COVID‐19 patients treated with tocilizumab: An individual patient data systematic review	78
The outcome of COVID‐19 in patients with hematological malignancy	78
Obesity predisposes to the risk of higher mortality in young COVID‐19 patients	78
Elevated MUC1 and MUC5AC mucin protein levels in airway mucus of critical ill COVID‐19 patients	78
Efficacy of tocilizumab in COVID‐19: A systematic review and meta‐analysis	77
Clinical and demographic characteristics of patients dying from COVID‐19 in Italy vs China	77
High prevalence of SARS‐CoV‐2 and influenza A virus (H1N1) coinfection in dead patients in Northeastern Iran	77
SARS‐CoV‐2 variants and vulnerability at the global level	76
The first reactive arthritis case associated with COVID‐19	76
Predictive values of blood urea nitrogen/creatinine ratio and other routine blood parameters on disease severity and survival of COVID‐19 patients	76
Systematic analysis of ACE2 and TMPRSS2 expression in salivary glands reveals underlying transmission mechanism caused by SARS‐CoV‐2	76
SARS‐CoV‐2 and SARS‐CoV: Virtual screening of potential inhibitors targeting RNA‐dependent RNA polymerase activity (NSP12)	76
The inflammatory markers of multisystem inflammatory syndrome in children (MIS‐C) and adolescents associated with COVID‐19: A meta‐analysis	76
Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID‐19 patients: A meta‐regression and decision tree analysis	75
COVID‐19 pneumonia treated with Sarilumab: A clinical series of eight patients	75
Role of toll‐like receptors in modulation of cytokine storm signaling in SARS‐CoV‐2‐induced COVID‐19	74
Recurrence of positive SARS‐CoV‐2 in patients recovered from COVID‐19	74
Extrapulmonary and atypical clinical presentations of COVID‐19	74
Vaginal delivery report of a healthy neonate born to a convalescent mother with COVID‐19	73
Elevated interleukin‐6 is associated with severity of COVID‐19: A meta‐analysis	73
Re‐emerging human monkeypox: A major public‐health debacle	73
Cycle threshold values in RT‐PCR to determine dynamics of SARS‐CoV‐2 viral load: An approach to reduce the isolation period for COVID‐19 patients	73
Herpes zoster emergence following mRNA COVID‐19 vaccine	72
Gendered effects on inflammation reaction and outcome of COVID‐19 patients in Wuhan	72
Risk factors and outcomes of COVID‐19 in New York City; a retrospective cohort study	71
Analytical and clinical validation of an ELISA for specific SARS‐CoV‐2 IgG, IgA, and IgM antibodies	71
The global epidemic of SARS‐CoV‐2 variants and their mutational immune escape	71
SARS‐CoV‐2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate?	71
Epidemiological features and viral shedding in children with SARS‐CoV‐2 infection	71
RNA‐dependent RNA polymerase of SARS‐CoV‐2 as a therapeutic target	71
Decontamination of face masks with steam for mask reuse in fighting the pandemic COVID‐19: Experimental supports	70
Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis	69
Vitamin D deficiency is associated with COVID‐19 positivity and severity of the disease	69
Clearance and persistence of SARS‐CoV‐2 RNA in patients with COVID‐19	69
SARS‐CoV‐2 S1 is superior to the RBD as a COVID‐19 subunit vaccine antigen	69
COVID‐19: A perspective on Africa's capacity and response	68
Long‐term coexistence of SARS‐CoV‐2 with antibody response in COVID‐19 patients	68
Immunoregulation with mTOR inhibitors to prevent COVID‐19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines	68
Microstructure, pathophysiology, and potential therapeutics of COVID‐19: A comprehensive review	68
COVID‐19 vaccinations: The unknowns, challenges, and hopes	68
Persistent viral RNA positivity during the recovery period of a patient with SARS‐CoV‐2 infection	67
Obesity a predictor of outcomes of COVID‐19 hospitalized patients—A systematic review and meta‐analysis	67
Clinical study evaluating the efficacy of ivermectin in COVID‐19 treatment: A randomized controlled study	67
The global impact of COVID‐19 pandemic on the incidence of pediatric new‐onset type 1 diabetes and ketoacidosis: A systematic review and meta‐analysis	66
Impact of COVID‐19 in patients with concurrent co‐infections: A systematic review and meta‐analyses	66
Omicron (B.1.1.529) variant of SARS‐CoV‐2: Concerns, challenges, and recent updates	66
Positive result of Sars‐Cov‐2 in faeces and sputum from discharged patients with COVID‐19 in Yiwu, China	66
Epidemiologic characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID‐19: A systematic review and meta‐analysis	65
Prolonged SARS‐CoV‐2 RNA detection in anal/rectal swabs and stool specimens in COVID‐19 patients after negative conversion in nasopharyngeal RT‐PCR test	65
Coronapp: A web application to annotate and monitor SARS‐CoV‐2 mutations	65
Pooling of nasopharyngeal swab specimens for SARS‐CoV‐2 detection by RT‐PCR	64
Defining IL‐6 levels in healthy individuals: A meta‐analysis	64
Clinical neurophysiology and cerebrospinal liquor analysis to detect Guillain‐Barré syndrome and polyneuritis cranialis in COVID‐19 patients: A case series	64
Serum KL‐6 concentrations as a novel biomarker of severe COVID‐19	64
COVID‐19 and coagulation dysfunction in adults: A systematic review and meta‐analysis	64
Genomic and proteomic mutation landscapes of SARS‐CoV‐2	64
Mortality risk with preadmission metformin use in patients with COVID‐19 and diabetes: A meta‐analysis	64
Cytomegalovirus, Epstein‐Barr virus, and human herpesvirus‐6 infections in patients with myalgic еncephalomyelitis/chronic fatigue syndrome	64
Placental SARS‐CoV‐2 in a pregnant woman with mild COVID‐19 disease	63
Acute hypertriglyceridemia in patients with COVID‐19 receiving tocilizumab	63
Serological tests facilitate identification of asymptomatic SARS‐CoV‐2 infection in Wuhan, China	63
Newly diagnosed diabetes mellitus, DKA, and COVID‐19: Causality or coincidence? A report of three cases	62
ACE2, TMPRSS2, and Furin variants and SARS‐CoV‐2 infection in Madrid, Spain	62
Understanding the pathophysiological changes via untargeted metabolomics in COVID‐19 patients	62
COVID‐19 vaccines mix‐and‐match: The concept, the efficacy and the doubts	62
Evidence of central nervous system infection and neuroinvasive routes, as well as neurological involvement, in the lethality of SARS‐CoV‐2 infection	61
Kidney involvement in COVID‐19 and its treatments	61
The management of coronavirus disease 2019 (COVID‐19)	61
Possible vertical transmission and antibodies against SARS‐CoV‐2 among infants born to mothers with COVID‐19: A living systematic review	61
The dynamic changes of serum IgM and IgG against SARS‐CoV‐2 in patients with COVID‐19	61
The outbreak of SARS‐CoV‐2 Omicron lineages, immune escape, and vaccine effectivity	60
Mutational and phylogenetic analyses of the two lineages of the Omicron variant	60
COVID‐19: Herd immunity and convalescent plasma transfer therapy	60
Evaluating the efficiency of specimen pooling for PCR‐based detection of COVID‐19	60
Optimization of group size in pool testing strategy for SARS‐CoV‐2: A simple mathematical model	59
In the age of Omicron variant: Paxlovid raises new hopes of COVID‐19 recovery	59
Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID‐19	59
Polymorphisms of ACE (I/D) and ACE2 receptor gene (Rs2106809, Rs2285666) are not related to the clinical course of COVID‐19: A case study	59
Late onset infectious complications and safety of tocilizumab in the management of COVID‐19	59
Monkeypox: A potential global threat?	59
In silico analyses on the comparative sensing of SARS‐CoV‐2 mRNA by the intracellular TLRs of humans	59